Genomic Activation of PPARG Reveals a Candidate Therapeutic Axis in Bladder Cancer

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• The PPARG gene, encoding the nuclear receptor PPARγ, is implicated in bladder cancer development.
• PPARG activation in bladder cancer can occur through gene amplification, mutation, or mutation of its heterodimeric partner, RXRA.

Purpose of the Study:

• To investigate the role of PPARG and RXRA alterations in bladder cancer.
• To identify a specific gene expression signature associated with PPARG/RXRA activation.
• To evaluate the therapeutic potential of targeting PPARG in bladder cancer.

Main Methods:

• Analysis of gene expression signatures in bladder cancers with PPARG or RXRA alterations.
• Pharmacologic inhibition and genetic ablation of PPARG activity in bladder cancer cells.
• Assessment of cancer cell proliferation following PPARG inhibition.

Main Results:

• Activating alterations in PPARG or RXRA lead to a distinct gene expression profile in bladder cancers.
• Inhibition of PPARG activity, via pharmacologic or genetic means, effectively suppressed the proliferation of PPARG-activated bladder cancer cells.

Conclusions:

• PPARG and RXRA alterations are key drivers in a subset of bladder cancers.
• Targeting PPARG represents a promising preclinical strategy for bladder cancer therapy.